PMID- 16285993
OWN - NLM
STAT- MEDLINE
DCOM- 20060209
LR  - 20151119
IS  - 0021-9150 (Print)
IS  - 0021-9150 (Linking)
VI  - 183
IP  - 2
DP  - 2005 Dec
TI  - Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary 
      heart disease: Atherosclerosis Risk in Communities study.
PG  - 301-7
AB  - Monocyte chemoattractant protein-1 (MCP-1), which mediates the recruitment of 
      monocytes, has been suggested to play a role in atherosclerosis. Because the 
      correlation between circulating MCP-1 and cardiovascular risk has not been 
      thoroughly investigated, we determined the relationship between MCP-1 level and 
      peripheral arterial disease (PAD) or coronary heart disease (CHD). In the 
      Atherosclerosis Risk in Communities (ARIC) study, 209 cases with lower extremity 
      PAD and 412 cases with incident CHD were compared with 733 and 709 subjects 
      without PAD and CHD, respectively. Mean plasma MCP-1 levels were significantly 
      higher in PAD cases (468.7 versus 416.5 pg/mL in non-cases). MCP-1 levels 
      correlated significantly with other inflammatory markers in comparison subjects. 
      Logistic regression analyses showed a significant association of MCP-1 with PAD, 
      independent of traditional CHD risk factors, with an odds ratio of 2.14 (95% CI, 
      1.28-3.60) for the highest MCP-1 tertile compared with the lowest. Incident CHD 
      risk increased significantly per 1 standard deviation (S.D.) difference in MCP-1 
      level independent of other cardiovascular risk factors, including inflammatory 
      markers. These data show that MCP-1 is associated with atherosclerotic disease in 
      two vascular beds and suggest that MCP-1 may be a novel target for 
      atherosclerosis therapy.
FAU - Hoogeveen, Ron C
AU  - Hoogeveen RC
AD  - Section of Atherosclerosis and Lipoprotein Research, Department of Medicine, 
      Baylor College of Medicine and Center for Cardiovascular Disease Prevention, 
      Methodist DeBakey Heart Center, 6565 Fannin, M.S. F-701, Houston, TX 77030, USA. 
      ronh@bcm.tmc.edu
FAU - Morrison, Alanna
AU  - Morrison A
FAU - Boerwinkle, Eric
AU  - Boerwinkle E
FAU - Miles, J Shawn
AU  - Miles JS
FAU - Rhodes, Charles E
AU  - Rhodes CE
FAU - Sharrett, A Richey
AU  - Sharrett AR
FAU - Ballantyne, Christie M
AU  - Ballantyne CM
LA  - eng
GR  - N01-HC-55015/HC/NHLBI NIH HHS/United States
GR  - N01-HC-55016/HC/NHLBI NIH HHS/United States
GR  - N01-HC-55018/HC/NHLBI NIH HHS/United States
GR  - N01-HC-55019/HC/NHLBI NIH HHS/United States
GR  - N01-HC-55020/HC/NHLBI NIH HHS/United States
GR  - N01-HC-55021/HC/NHLBI NIH HHS/United States
GR  - N01-HC-55022/HC/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20050414
PL  - Ireland
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
RN  - 0 (Biomarkers)
RN  - 0 (Chemokine CCL2)
SB  - IM
MH  - Atherosclerosis/blood/*epidemiology
MH  - Biomarkers/blood
MH  - Chemokine CCL2/*blood
MH  - Constriction, Pathologic
MH  - Coronary Disease/*blood/epidemiology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Peripheral Vascular Diseases/*blood/epidemiology
MH  - *Population Surveillance
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - Risk Factors
MH  - United States/epidemiology
EDAT- 2005/11/16 09:00
MHDA- 2006/02/10 09:00
CRDT- 2005/11/16 09:00
PHST- 2004/12/28 00:00 [received]
PHST- 2005/02/17 00:00 [revised]
PHST- 2005/03/02 00:00 [accepted]
PHST- 2005/11/16 09:00 [pubmed]
PHST- 2006/02/10 09:00 [medline]
PHST- 2005/11/16 09:00 [entrez]
AID - S0021-9150(05)00195-4 [pii]
AID - 10.1016/j.atherosclerosis.2005.03.007 [doi]
PST - ppublish
SO  - Atherosclerosis. 2005 Dec;183(2):301-7. doi: 
      10.1016/j.atherosclerosis.2005.03.007. Epub 2005 Apr 14.